Available Technologies

Browse Penn-owned technologies available for licensing.


Search Results - immunotherapy

3 Results Sort By:
Lipid nanoparticle-based mRNA delivery for CAR T-cell engineering
A library of ionizable lipid nanoparticles (LNPs) was screened for ability to deliver mRNA to T-cells, leading to an optimized LNP formulation for delivery of mRNA to T-cells. This thereby enhances the ability to generate transient chimeric antigen receptor (CAR)-expressing T-cells for cancer immunotherapy.Problem: Chimeric antigen receptor (CAR) T-cells...
Published: 5/4/2020   |   Inventor(s): Margaret Billingsley, Carl June, Nathan Singh, Michael Mitchell
Keywords(s): Bioengineering, COVID-19, Drug Delivery, Immunology, Immunotherapy
Category(s): Therapeutics & Vaccines
Tumor mitochondria vaccine for the treatment of cancer
Problem: Progression in cancer immunotherapy has been rapid with a number of products currently available and many others in late stage clinical development. However, clinical response to immunotherapies is variable and dependent on cancer types as well as specific characteristics or genetic mutations within a patient’s individual tumor. There...
Published: 1/23/2020   |   Inventor(s): Andrea Facciabene
Keywords(s): Immunotherapy, Oncology, Vaccine
Category(s): Therapeutics & Vaccines
Immunotoxin Therapeutic Targets Epithelial Derived Cancers
Immunotoxin chimeras of DNaseI and cytolethal distending toxin (CdtB subunit) are an effective therapeutic against epithelial tumors. Technology Overview: Immortalized epithelioid cell lines are sensitive to CdtB, whereas cells of mesenchymal, or ectomesenchymal origin are relatively resistant. Unique chimeras of the cdtB gene and human type I...
Published: 11/27/2018   |   Inventor(s): Joseph Dirienzo
Keywords(s): Immunotherapy, Oncology, Therapeutics
Category(s): Therapeutics & Vaccines